Esperion Expects Speedy Regulatory Path For Bempedoic Acid/Zetia Combo

Company plans to file the fixed-dose combination through FDA's 505(b)2 pathway, alongside a filing for bempedoic acid itself.

Esperion Therapeutics Inc. says it has FDA's blessing to use the 505(b)2 pathway to submit a combination of its cholesterol drug bempedoic acid with Merck & Co. Inc.'s Zetia (ezetimibe), referencing both Zetia and a parallel NDA for bempedoic acid.

Bempedoic acid inhibits ATP citrate lyase, an enzyme on the cholesterol biosynthesis pathway, and is part of a wave of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards